Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 4,259 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Sadie Stern also recently made the following trade(s):

• On Monday, September 9th, Sadie Stern sold 426 shares of DexCom stock. The stock was sold at an average price of $69.15, for a total value of $29,457.90.

DexCom Price Performance

Shares of DXCM opened at $72.83 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company’s fifty day simple moving average is $70.61 and its 200 day simple moving average is $89.83. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a market cap of $28.45 billion, a price-to-earnings ratio of 43.61, a PEG ratio of 2.28 and a beta of 1.17.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DXCM. Virtu Financial LLC acquired a new stake in DexCom in the 3rd quarter valued at about $1,020,000. Toronto Dominion Bank raised its stake in DexCom by 3.1% in the third quarter. Toronto Dominion Bank now owns 204,522 shares of the medical device company’s stock valued at $13,711,000 after buying an additional 6,227 shares during the period. Coldstream Capital Management Inc. lifted its position in shares of DexCom by 45.3% in the third quarter. Coldstream Capital Management Inc. now owns 11,253 shares of the medical device company’s stock valued at $781,000 after buying an additional 3,508 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after acquiring an additional 214,136 shares during the period. Finally, Brophy Wealth Management LLC acquired a new position in shares of DexCom during the 3rd quarter worth approximately $337,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on DXCM. Oppenheimer lowered their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Piper Sandler restated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Robert W. Baird boosted their price objective on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. Sanford C. Bernstein increased their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.